Cardinal Health, Inc.

Fundamentals6.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • High revenue volume
  • Thin profitability
  • Negative equity/liquidity

AI
AI Summary

6.0

Cardinal Health has shifted from a low‑margin distributor into a cash‑generating, specialty‑focused operator whose re‑rating now depends on flawless execution of multiple integrations and sustained specialty margin expansion—if CAH meets FCF/deleveraging targets and reclaims 223–230 on volume the upside is material, but missed integrations, tariff or financing shocks would quickly erase gains.

SpecialtyGrowth
ExecutionRisk
Leverage‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • High revenue volume
  • Thin profitability
  • Negative equity/liquidity

Cardinal Health is a high‑volume, cash‑generative distributor with thin margins and manageable absolute debt but concerning liquidity and negative shareholders' equity that raise solvency risk. #balance-sheet‌

cashgenerative

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Short-term downtrend
  • Clustered resistance
  • Support testing

CAH is in a short-term downtrend after closing well below its last-month SMA and losing ground from ~$229.88 to $207.88, with immediate support at ~$207.88 and clustered resistance at $223–$230 that must be reclaimed to resume bullish momentum.

bearish
Support Level: $207.88 (nearby $210.92, $211.87)
Resistance Level: $223–$230

Rapid decline from ~$229.88 (early

Sentiment & News

7.0

Key News Insights:

  • Strong cash flow
  • Specialty acceleration
  • Institutional shifts

Cardinal Health is reporting strong free cash flow and accelerating specialty/biosimilars momentum with robust revenue/EPS guidance, driving generally positive share performance amid active institutional repositioning.

OperationalStrength
InvestorRepositioning

The combination of solid cash generation and expanding specialty/biosimilars exposure should support valuation upside and confidence in execution, though investor reallocations could add near-term volatility